Prentice Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Prentice Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-390,381	Closed	-$1.29M	–	35
2020 Q3	$1.29M	Sell	390,381 -38,495	-9%	-$141K	0.49%	15
2020 Q2	$1.45M	Buy	428,876 +87,440	+26%	+$413K	0.53%	16
2020 Q1	$1.31M	Buy	341,436 +131,820	+63%	+$612K	0.62%	25
2019 Q4	$1.27M	Buy	+209,616	New	+$1.43M	0.6%	17

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Prentice Capital Management's ZYNE Position: Q4 2020 in Review

Prentice Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 390,381 shares — an estimated $1.29M sold.

Prentice Capital Management first reported a position in ZYNE in Q4 2019 and held it in 4 quarters. The position peaked at $1.45M in Q2 2020. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

Prentice Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
Prentice Capital Management sold 390,381 Zynerba Pharmaceuticals, Inc shares in Q4 2020, an estimated $1.29M.
Prentice Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2019 and held it in 4 quarters.
Prentice Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $1.45M in Q2 2020.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on Prentice Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.